YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure

Not Applicable

Completed

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Other: Best practice alert for the notification of patient HFrEF and recommended evidence-based therapies (NO drugs are being administered in this trial)

First Posted Date: 2020-08-17

Last Posted Date: 2022-12-09

Lead Sponsor: Yale University

Target Recruit Count: 48

Registration Number: NCT04514458

Locations: 🇺🇸
Yale New Haven Health System selected outpatient clinics, New Haven, Connecticut, United States

Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations

Completed

Conditions: Opioid Use
Opioid Prescribing

Interventions: Drug: Short-acting opioid prescription for acute pain

First Posted Date: 2020-08-11

Last Posted Date: 2023-12-05

Lead Sponsor: Yale University

Target Recruit Count: 1709

Registration Number: NCT04509115

Locations: 🇺🇸
University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 2 locations

Sensory Basis of Speech Motor Learning

Not Applicable

Recruiting

Conditions: Speech
Consolidation

Interventions: Behavioral: Adaptation
Other: cTBS

First Posted Date: 2020-08-04

Last Posted Date: 2024-03-25

Lead Sponsor: Yale University

Target Recruit Count: 160

Registration Number: NCT04497428

Locations: 🇨🇦
McGill University, Montréal, Quebec, Canada

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Phase 1

Active, not recruiting

Conditions: Advanced Melanoma
Renal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: APX005M

First Posted Date: 2020-07-31

Last Posted Date: 2024-06-21

Lead Sponsor: Yale University

Target Recruit Count: 26

Registration Number: NCT04495257

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Smoking by IV Pulsed Nicotine

Early Phase 1

Completed

Conditions: Smoking Cessation

Interventions: Drug: Nicotine 0.2mcg/kg/s and 1.0mcg/kg/s

First Posted Date: 2020-07-28

Last Posted Date: 2021-07-20

Lead Sponsor: Yale University

Target Recruit Count: 13

Registration Number: NCT04488744

Locations: 🇺🇸
Veterans Affairs Hospital, West Haven, Connecticut, United States

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

Phase 4

Active, not recruiting

Conditions: Tobacco Use Cessation

Interventions: Drug: Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler
Drug: Varenicline or bupropion
Behavioral: Contingency Management

First Posted Date: 2020-07-28

Last Posted Date: 2025-01-09

Lead Sponsor: Yale University

Target Recruit Count: 320

Registration Number: NCT04490057

Locations: 🇺🇸
SUNY Downstate STAR Clinic, Brooklyn, New York, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

and more 1 locations

Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial

Phase 3

Completed

Conditions: SARS-CoV-2

Interventions: Drug: Standard of Care (SOC) and Colchicine+Rosuvastatin

First Posted Date: 2020-07-15

Last Posted Date: 2023-04-27

Lead Sponsor: Yale University

Target Recruit Count: 250

Registration Number: NCT04472611

Locations: 🇺🇸
Bridgeport Hospital, Bridgeport, Connecticut, United States
🇺🇸
Lawrence & Memorial Hospital, New London, Connecticut, United States
🇺🇸
Yale New Haven Hosptial System, New Haven, Connecticut, United States

and more 1 locations

Heart Watch Study: a Pragmatic Randomized Controlled Trial

Not Applicable

Completed

Conditions: Cardioversion
Atrial Fibrillation

Interventions: Device: Apple Watch
Device: Withings Move

First Posted Date: 2020-07-13

Last Posted Date: 2024-12-20

Lead Sponsor: Yale University

Target Recruit Count: 150

Registration Number: NCT04468321

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Phase 1

Active, not recruiting

Conditions: Early Course Schizophrenia Spectrum Disorder

Interventions: Drug: CVL-562 (PF-06412562) 1 mg
Drug: CVL-562 (PF-06412562) 4 mg
Drug: CVL-562 (PF-06412562) 15 mg
Drug: CVL-562 (PF-06412562) 25 mg
Other: Placebo

First Posted Date: 2020-07-07

Last Posted Date: 2024-05-08

Lead Sponsor: Yale University

Target Recruit Count: 120

Registration Number: NCT04457310

Locations: 🇺🇸
Stony Brook University, Stony Brook, New York, United States
🇺🇸
Columbia University, New York, New York, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 1 locations

Infrared Wraps Effect on Oxygenation of Diabetics Arm, Feet and Lower Leg

Not Applicable

Completed

Conditions: Diabetes

Interventions: Device: Active IR sock
Other: Placebo socks

First Posted Date: 2020-07-07

Last Posted Date: 2022-07-14

Lead Sponsor: Yale University

Target Recruit Count: 39

Registration Number: NCT04460612

Locations: 🇺🇸
Endocrine Associates Of Connecticut, Hamden, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy